Valuation: NetraMark Holdings Inc.

Market Cap 7.7Cr 5.42Cr 4.75Cr 4.38Cr 4.06Cr 514.87Cr 7.82Cr 52Cr 20Cr 254.1Cr 20Cr 20Cr 878.28Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 7.7Cr 5.42Cr 4.75Cr 4.38Cr 4.06Cr 514.87Cr 7.82Cr 52Cr 20Cr 254.1Cr 20Cr 20Cr 878.28Cr EV / Sales 2026 *
192x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
1 day-1.20%
1 week+30.16%
Current month+30.16%
1 month-4.65%
3 months-2.38%
6 months-19.61%
Current year-25.45%
1 week 0.6
Extreme 0.6
0.83
1 month 0.59
Extreme 0.59
0.88
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.8
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
2.39
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Date Insider Type Main position Quantity % Market Cap.
14/04Sell

Chief Technology Officer

14,286 0.0154%
13/04Tax

Chairperson

4,34,178 0.4686%
09/04Tax

Chairperson

1,77,611 0.1917%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%+30.16%-36.92%+198.18% 5.41Cr
+1.92%+5.63%-20.83%+16.85% 2,87300Cr
+3.40%+17.60%-1.38%+794.39% 32TCr
+1.33%-6.34%+277.76%+899.96% 13TCr
-0.92%-1.16%+15.82%+63.50% 10TCr
+4.74%+2.70%+75.44%+172.79% 9.09TCr
-1.26%-1.98%-18.50%+1.38% 8.47TCr
+0.35%+9.96%-30.27%+91.66% 6.43TCr
+0.19%+3.59%+6.77%+80.84% 4.8TCr
-0.37%+4.58%-47.23%+38.20% 4.08TCr
Average +0.81%+7.45%+22.07%+235.78% 37.5TCr
Weighted average by Cap. +1.77%+5.23%-5.80%+119.62%

Financials

2026 *2027 *
Net sales 4L 3L 2L 2L 2L 2.68Cr 4L 27.32L 10.63L 1.32Cr 10.61L 10.38L 4.57Cr -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
07/26/07 CA$0.8200 -1.20% 24,000
06/26/06 CA$0.8300 +3.75% 22,003
03/26/03 CA$0.8000 +6.67% 39,002
02/26/02 CA$0.7500 +19.05% 1,40,303
30/26/30 CA$0.6300 +1.61% 1,40,002

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock